AVITA Medical (ASX:AVH) has finalised a ten-year agreement with the Biomedical Advanced Research and Development Authority valued at up to $25.5 million.
The partnership, established under Project BioShield, is designed to fortify national preparedness for burn mass casualty incidents by ensuring rapid, large-scale access to the company's proprietary RECELL technology.
Under the terms of the contract, AVITA Medical will receive approximately $3.97 million in guaranteed revenue over the decade for providing ongoing readiness support and maintaining a dedicated inventory for immediate deployment.
The remaining balance of the contract value is tied to procurement options that BARDA may exercise to secure up to 3,000 units.
Beyond mere supply, the agreement mandates that AVITA oversees the logistics, quality assurance, and deployment readiness required to integrate these medical devices into designated emergency centres nationwide.
Interim CEO Cary Vance emphasised that the collaboration underscores a commitment to delivering life-saving wound care innovation when the nation’s medical systems face extreme surge pressures.
By providing discounted pricing and robust manufacturing compliance, AVITA Medical continues a decade-long relationship with the US Department of Health and Human Services.